OR4P4 Inhibitors
OR4P4 inhibitors fall into several classes based on the signaling pathways they affect. The first class includes PI3K inhibitors like LY294002 and Wortmannin. These compounds block the PI3K/AKT pathway, a key regulator of many cellular processes including GPCR signaling. By inhibiting PI3K, LY294002 and Wortmannin would lead to reduced AKT phosphorylationand activity, potentially causing decreased activation of downstream effectors that may be necessary for OR4P4 function. Given that G protein-coupled receptors (GPCRs) like OR4P4 often rely on PI3K/AKT for signal transduction, their inhibition effectively reduces OR4P4's ability to propagate its signal within the cell. Another PI3K pathway inhibitor, Dactolisib, and the pan-class I PI3K inhibitor Buparlisib function similarly, potentially reducing OR4P4 activity through the same mechanism.
The second class of OR4P4 inhibitors targets the MAPK/ERK and p38 MAPK pathways. U0126, a MEK1/2 inhibitor, and ZM 336372, a RAF kinase inhibitor, both suppress the MAPK/ERK signaling cascade. This cascade is crucial for many GPCR functions, and its inhibition would likely lead to decreased OR4P4 activity, assuming OR4P4 uses this pathway to exert its effects. Similarly, PD 169316 and SB203580, both p38 MAPK inhibitors, would diminish OR4P4 function if p38 MAPK is involved in the receptor's signaling. JNK pathway inhibitor SP600125 could also decrease OR4P4 activity by disrupting stress and inflammatory response pathways that may modulate OR4P4 function. Gö 6983's inhibition of PKC isoforms could lead to reduced OR4P4 activity, as PKC is known to phosphorylate and regulate GPCRs. Inhibition of mTOR by Rapamycin could indirectly decrease OR4P4 activity by affecting protein synthesis and cell proliferation, processes that could be vital for the optimal functioning of OR4P4. Lastly, Palbociclib's role in halting cell cycle progression through CDK4/6 inhibition could lead to decreased OR4P4 activity if OR4P4's function is tied to cell cycle events.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of PI3K, LY294002 binds to the ATP-binding site of PI3K, preventing its activity. PI3K is critical for the activation of AKT signaling, which can regulate a variety of cellular processes including those associated with GPCR function. Inhibition of PI3K would reduce AKT phosphorylation and activity, likely leading to decreased functional activity of OR4P4 if OR4P4 signaling is AKT-dependent. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that irreversibly binds to PI3K, inhibiting its activity. By halting PI3K activity, downstream AKT signaling is diminished, which could lead to decreased OR4P4 activity if its signaling is coupled to the PI3K/AKT pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2, U0126 prevents the activation of MAPK/ERK pathway by inhibiting MEK, which is upstream of ERK. As the MAPK/ERK pathway can regulate GPCR function, inhibition here could lead to a decrease in OR4P4 activity if it relies on this pathway for signaling. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
ZM 336372 is a potent RAF kinase inhibitor, which could disrupt the MAPK/ERK signaling. Since RAF is an upstream kinase in this pathway, its inhibition could lead to decreased signaling through ERK and potentially reduce OR4P4 activity if OR4P4 is dependent on this pathway. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
A selective p38 MAPK inhibitor, PD 169316 prevents the phosphorylation and activation of p38 MAPK. If OR4P4 signaling involves p38 MAPK, inhibition by PD 169316 would result in decreased functional activity of OR4P4. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAPK, blocking its kinase activity. This reduces the signaling through p38 MAPK-dependent pathways, which could lead to decreased OR4P4 activity if OR4P4 signaling is mediated through p38 MAPK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A selective inhibitor of JNK, SP600125 binds to the ATP-binding site of JNK, inhibiting its activity. As JNK is involved in stress and inflammatory responses, its inhibition could lead to decreased OR4P4 activity if OR4P4 is modulated through JNK-dependent pathways. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö 6983 is a broad-spectrum PKC inhibitor that can prevent the phosphorylation of proteins by PKC isoforms. Since PKC can regulate GPCR function, Gö 6983 could decrease OR4P4 activity if PKC phosphorylation is necessary for OR4P4 function. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
A dual PI3K/mTOR inhibitor, Dactolisib disrupts signaling through both PI3K and mTOR pathways. Given the role of these pathways in regulating GPCR activity, Dactolisib could lead to decreased OR4P4 activity if OR4P4 relies on PI3K/mTOR for signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that binds to FKBP12 and the resulting complex inhibits mTORC1. Reduced mTORC1 activity can lead to decreased protein synthesis and cell proliferation, potentially decreasing OR4P4 activity if mTOR signaling affects OR4P4 function. | ||||||